Novel therapies, including enzastaurin, in the treatment of ovarian cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapies, including enzastaurin, in the treatment of ovarian cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 5, Pages 579-598
Publisher
Informa Healthcare
Online
2014-03-22
DOI
10.1517/13543784.2014.900542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.
- (2017) A. J. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
- (2017) J. D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.
- (2017) D. D. Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
- (2017) J. A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.
- (2017) R. W. Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
- (2017) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)—European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial.
- (2017) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation
- (2014) Karen Bräutigam et al. Translational Oncology
- Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
- (2013) Robert Dreicer et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
- (2013) Noriyuki Katsumata et al. LANCET ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
- (2012) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract 2570: Combination studies of EC145 with approved anti-cancer drugs for ovarian cancer
- (2012) Joseph A. Reddy et al. CANCER RESEARCH
- Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
- (2012) Nwabundo Nwankwo et al. INVESTIGATIONAL NEW DRUGS
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
- (2011) Sukhmani K. Padda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies
- (2011) Lydia Usha et al. GYNECOLOGIC ONCOLOGY
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
- (2011) Christiane Querfeld et al. LEUKEMIA & LYMPHOMA
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells
- (2010) Isabelle Cadron et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer
- (2010) Ignace Vergote et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
- (2010) Alberto Chiappori et al. Journal of Thoracic Oncology
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
- (2009) A.-R. Hanauske et al. ANNALS OF ONCOLOGY
- A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
- (2009) D. Ross Camidge et al. ANTI-CANCER DRUGS
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
- (2009) Andreas du Bois et al. CANCER
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
- (2009) Susan J. Ramus et al. Molecular Oncology
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
- (2008) Amancio Carnero et al. CURRENT CANCER DRUG TARGETS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More